Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Colby gets exclusive rights to MannKind's cancer immunotherapy program

Executive Summary

Colby Pharmaceutical Co. (signal transduction modulators and immune modulators for various diseases) has licensed exclusive worldwide rights to develop and sell diabetes and cancer firm MannKind Corp.’s disease-specific antigen compounds and associated intra-lymph node injection (ILNI) delivery technologies from the company’s MKC1106 immunotherapy program, including lead candidate MKC1106MT.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies